25 jul: Symantec 1st-Quarter Net Down 9.9% on Costs; CEO Enrique Salem St..
25 jul: Turkey Business Confidence Falls in July
25-07-2012 14:05:00

Bristol-Myers Profit Falls 28%

Relateret indhold
Relateret debat
18 jan - 
UK Assignment Writing Help Service Say: Current capabil..
18 jan - 
Sanofi Outlines Next Wave of Innovative Medicines and V..
02 jan - 
Super godt indlæg! Tak for det. :)

Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix.

The New York drug maker also lowered its forecast of full-year 2012 earnings.

Bristol-Myers plans to get through the patent losses for Plavix and other drugs by boosting sales of newer drugs. The company hopes to bolster its product lineup with its recent agreement to purchase diabetes-drug maker Amylin Pharmaceuticals Inc. (AMLN) for $5.3 billion.

In May, Bristol-Myers lost U.S. patent protection for Plavix, which is used to stave off recurrent heart attacks and strokes. This exposed the brand to lower-priced competition from generic versions, and Bristol's second-quarter Plavix sales tumbled 60% to $741 million. Bristol-Myers co-markets the drug with Sanofi (SNY).

Another blow was the March loss of patent protection for blood-pressure medications Avapro and Avalide, which pushed combined sales of those drugs down 53% to $117 million.

Bristol and other drug makers are in the midst of a wave of patent expirations for blockbuster drugs that have pressured sales. Bristol has had some success bringing new drugs to market to help offset the patent losses, but it also has experienced some research setbacks.

For the second quarter, Bristol's profit fell to $645 million, or 38 cents a share, from $902 million, or 52 cents a share, a year earlier. Excluding certain costs such as asset impairments, earnings were 48 cents a share, matching the mean estimate of analysts surveyed by Thomson Reuters.

Overall sales declined 18% to $4.44 billion, just ahead of the Thomson mean estimate.

U.S. sales dropped 27% to $2.6 billion, while non-U.S. sales fell 1% to $1.9 billion.

Although sales for Plavix and the blood-pressure medications declined substantially, sales for other top products increased, ranging from a 1% gain for antipsychotic Abilify to a 71% jump for skin-cancer treatment Yervoy.

Bristol-Myers continues to try to bring more drugs to market. One of the most closely watched is Eliquis, an anticlotting drug co-developed with Pfizer Inc. (PFE). The U.S. Food and Drug Administration declined to approve it in June, asking for more information about clinical data. Analysts believe the drug could be a multibillion-dollar seller.

Bristol also is developing new drugs for cancer and hepatitis C that have shown promise in studies.

The company, however, recently disclosed negative clinical results for experimental liver-cancer drug brivanib. And the FDA has declined to approve the diabetes drug dapagliflozin, developed in partnership with AstraZeneca PLC (AZN).

Bristol said Wednesday an advisory committee of the European Union issued a positive opinion on the company's proposed subcutaneous formulation of anti-inflammatory drug Orencia. A European Commission decision is pending.

The company lowered its forecast of 2012 earnings to a range of $1.78 to $1.88 a share from a prior range of $1.90 to $2 a share. However, Bristol didn't change its forecast of adjusted earnings, which exclude certain items, of $1.90 to $2 a share. Bristol said the unchanged adjusted earnings forecast factors in the expected three-cents-a-share negative impact related to the planned Amylin acquisition.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 25, 2012 08:05 ET (12:05 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/middag: Nordea nyder fortsat godt af regnskabssucces

29-01-2015 11:44:44
Støttet af positive kursmålsændringer lægger Nordea sig torsdag middag i spidsen af C20 Cap-indekset, der langsomt er krøbet mod nul-linjen efter en start på ha..

Vestas, Siemens og GE stod for 95 pct. af USA-markedet i 2014

29-01-2015 07:29:35
Der er tre totalt dominerende aktører på det amerikanske vindmøllemarked, og det er General Electric (GE), Siemens og Vestas.De tre vindmølleproducenter stod fo..

Spar Nord kan blive presset til blokade i Nørresundby-salg

28-01-2015 16:04:45
Spar Nord kan fortsat ende med at stille sig i vejen for Nordjyske Banks køb af Nørresundby Bank, selv om Spar Nord tidligere i januar trak sig fra budkrigen.Be..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Torm nærmer sig ny redningskrans med betingelser - NY
2
Aktier/tendens: Coloplast kommer med tal i rødt marked
3
Mærsk Mc-Kinney Møller sætter rekord for flest containere
4
Siemens faldt igen til bunds efter analytikerklø
5
Vestas, Siemens og GE stod for 95 pct. af USA-markedet i 2014

Relaterede aktiekurser

Sanofi 82,14 0,2% Stigning i aktiekurs
Astrazeneca PLC ORD SHS .. 4.780,00 0,8% Stigning i aktiekurs
Astrazeneca PLC 71,01 0,0% Aktiekurs uændret
Sanofi 46,05 0,0% Aktiekurs uændret
Bristol-Myers Squibb Co 61,33 0,0% Aktiekurs uændret
Pfizer Inc 31,95 0,0% Aktiekurs uændret
AstraZeneca PLC 596,00 0,9% Stigning i aktiekurs
Pfizer Inc 264,50 -0,8% Fald i aktiekurs
Pfizer 29,50 0,2% Stigning i aktiekurs
Pfizer Incorporated COM .. 32,27 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. januar 2015 13:21:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150128.1 - EUROWEB4 - 2015-01-29 13:21:12 - 2015-01-29 13:21:12 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x